Oxford Gene Technology (OGT), the molecular genetics company, today announces a strategic realignment of its commercial operations to fuel further growth in its high value genomics products portfolio. As part of this realignment, OGT will transfer its next generation sequencing services business to Source BioScience (LSE: SBS). Financial details were not disclosed.

Mike Evans, CEO of OGT commented, “Our strategic focus on the large and growing genomic medicine markets of cancer, molecular cytogenetics and reproductive health has delivered significant commercial growth. OGT’s genomics products portfolio has been growing at a compound annual growth rate of over 60% over the last four years and we have thus aligned our strategy and resources behind our genomics product business.”

OGT’s high-growth, product-focussed, strategy has been exemplified through the acquisition of Cytocell, a leading provider of fluorescence in situhybridisation (FISH) probes, in 2014, and its subsequent successful integration. OGT now has a strong, rapidly growing, core business comprised of CytoSure arrays and Cytocell FISH probes, with further product growth opportunities from its recently launched SureSeq range of cancer panels and its CytoSure Affirm non-invasive pre-natal test (NIPT) currently in clinical trials.

Mike Evans commented further on OGT’s transfer of its services business, “We will be providing our genetics analysis service customers with a high calibre alternative to OGT. We have worked closely with Source BioScience, well known as a trusted provider of state-of-the-art laboratory services, to ensure our customers will continue to receive best-in-class service and support, coupled with a seamless transition. Furthermore, OGT’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the consistent, high quality, genetic analysis that OGT provides.”

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

For more information, please visit at www.ogt.com.

CytoSure™ and SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell: Some products may not be available in the US.

About Source BioScience

Source BioScience is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries.

It is an international business operating nine state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.